勃起功能障碍（erectile dysfunction, ED）在中、老年男性中的发病率达到52%，ED与血管高危因子及血管疾病密切相关。但目前主要开发及应用的口服药物（PDE5抑制剂）只是诱发一时性勃起的平滑肌舒张剂，不能改善阴茎血管病变，并在30-50% ED患者中治疗效果不佳。最近很多研究者试图利用单一血管生成因子开发ED的长期治疗法，但还没有一种进入临床试验。说明用单一因子不能长效治疗阴茎血管病变。我们在前期研究中发现脂肪干细胞比骨髓细胞有更高的血管再生能力，并首次用其在糖尿病小鼠ED模型中诱导阴茎血管再生。在高脂血症小鼠ED模型中，阴茎内注射腺病毒-Comp-Angiopoietin-1或其蛋白质，使勃起能力恢复至注射后8周。本课题旨在结合多种方法（脂肪干细胞/ Comp-Angiopoietin-1基因或蛋白质）开发高效的血管再生技术，长效治疗ED。

Erectile dysfunction affects up to 52% in 40-70 old men which is closely related with vascular risk factors and vascular disease. But recently developed oral medication (PDE5 inhibitors) is smooth muscle relaxant which induces temporary erection and cannot fundamentally improve penile vascular pathological changes. 30%-50% of patients with ED respond poorly to it. Presently many researchers attempted to develop a fundamental therapy of ED with a single angiogenesis factor, but it has not been in the clinical trials. This suggests that single angiogenic factor cannot fundamentally cure penile vascular disease. Our previous study has shown that adipose tissue-derived stem cells can promote angiogenesis better than bone marrow stem cells. We used them to induce penile neoangiogenesis in diabetic ED mouse model. In ED mouse model induced by hypercholesterolemia, intracavernous injection of adenovirus Comp-Angiopoietin-1 and Comp-Angiopoietin-1 protein can recovery the erectile function up to 8 weeks after injection. The objective of this study is to develop an effective neoangiogenesis technique using multiple approach methods(cell/gene/protein theraphy) and fundamentally cure ED.